|
1）Dignass A, Van Assche G, Lindsay JO, et al. Travis for the European Crohns and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohns disease: Current management. Journal of Crohns and Colitis. 2010; 4: 28-62
|
|
|
|
|
2）Rutgeerts P, Haens GR, Van Assche G, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohns disease [ACCENTⅠ]. Gastrointest Endosc. 2006; 63: 433-441
|
|
|
|
|
3）Hanauer SB, Sandoborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohns disease: the CLASSIC-I Trial. Gastroenterology. 2006; 130: 323-33
|
|
|
|
|
|
4）Sandoborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohns disease: results of the CLASSIC Ⅱ trial. Gut. 2007; 56: 1232-9
|
|
|
|
|
|
5）Colombel JF, Sandoborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohns disease: The CHARM Trial. Gastroenterology. 2007; 132: 52-65
|
|
|
|
|
|
6）Feagan BG, Lemann M, Befrits R, et al. Recommendations for the treatment of Crohns disease with tumor necrosis factor antagonists: An expert consensus report. Inflamm Bowel Dis. 2012; 18: 152-60
|
|
|
|
|
|
7）Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of mainte-nance therapy with infliximab in Crons disease. Inflamm Bowel Dis. 2009; 15: 1295-301
|
|
|
|
|
|
8）Panaccione R, Colombel JF, Sandoborn WJ, et al. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohns disease. Aliment Pharmacol Ther. 2010; 31: 1296-309
|
|
|
|
|
|
9）Bernstein CN. Anti-tumor necrosis factor therapy in Cronhs disease: more information and more questions about the long term. Clin Gastroenterol Hepatol. 2010; 8: 556-8
|
|
|
|
|
|
10）Sorrentino D, Paviotti A, Terrosu G, et al. Low-dose maintenance therapy with infliximab pre-vents postsurgical recurrence of Crohns disease. Clin Gastroenterol Hepatol. 2010; 8: 591-9
|
|
|
|
|
|
11）Haens GD, Assche GV, Caenepeel P, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohns disease: a open randomized trial. Lancet. 2008; 371: 660-7
|
|
|
|
|
|
12）松本譽之．クローン病治療指針改訂案（平成22年度）．厚生労働科学研究費補助金難治性疾患克服研究事業難治性炎症性腸管障害に関する調査研究（渡辺班）．平成22年度分担研究報告書．2010. p.15-8
|
|
|
|
|
|
13）Lichtenstein GR, Hanauer SB, Sandborn WJ, The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohns Disease in Adults. Am J Gastroemtero-logy. 2009; 104(2): 465-83
|
|
|
|
|
|
14）Mowat C, Cole A, Windsor AI, et al. On behalf of the IBD Section of the British Society of Gastro-enterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011; 60(5): 571-607
|
|
|
|
|
|
15）DHaens GR, Panaccione R, Higgins PDR, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohns and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011; 106(2): 199-212
|
|
|
|
|
|
16）Loly C, Belaiche J, Louis E. Predictors of severe Crohns disease. Scand J Gastroenterology. 2008; 43: 948-54
|
|
|
|
|
|
17）Seksik P, Loftus EV, Beaugerie L, et al. Validation of predictors of 5-year disabling CD in a popula-tion-based cohort from Olmsted Country, Minne-sota1983-1996. Gastroenterology. 2007; 132: A-17
|
|
|
|
|
|
18）Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for Ulcerative Colitis. N Engl J Med. 2005; 353: 2462-76
|
|
|
|
|
|
19）Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004; 53: 1813-6
|
|
|
|
|
|
20）Colombel JF, Sandoborn WJ, Reinisch W, et al. Infliximab, Azatioprine, or combination therapy for Cronhs disease. N Engl J Med. 2010; 362: 1383-95
|
|
|
|
|
|
21）Asshe GV, Magdekane-Bwuzelin C, Haens GD, et al. Withdrawal of immunosuppression in Crohns diease treated with scheduled infliximab maintenance: A randomized trial Gastroen-terology. 2008; 134: 1861-8
|
|
|
|
|
|
22）Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children. Arthritis Rheum. 2010; 62(8): 2517-24
|
|
|
|
|
|
23）Fukunaga K,Yokoyama Y, Kamikozuru K, et al. Selective depletion of peripheral granulocyte/monocyte enhances the efficacy of scheduled maintenance infliximab in Crohns disease. J Clin Apher. 2010; 25: 226–8
|
|
|
|
|
|
24）Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adosorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009; 104(12): 2990-5
|
|
|
|
|
|
25）Suzuki Y, Yoshimura N, Fukuda K, et al. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci. 2006; 51: 2031-8
|
|
|
|
|
|
26）Matsumoto T, Andoh A , Okawa K, et al. Multivariate analysis for factors predicting rapid response of leukocytapheresis in patients with steroid-resistant ulcerative colitis: a multicenter prospective open-label study. Ther Apher Dial. 2008; 12(6): 484–90
|
|
|
|
|
27）Takayama T, Kanai T, Matsuoka K, et al. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. J Crohns Colits. 2012 (in press).
|
|
|
|
|
|
28）Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative coltitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010; 16: 1905-11.
|
|
|
|
|
|
29）Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis. 2012; 18: 803-8.
|
|
|
|
|